The DOI matches its Crossref record; 43 of the 43 references it cites were found in a registry or an index.
Uptake of particulate vaccine adjuvants by dendritic cells activates the NALP3 inflammasome
Open accessAbstract
Many currently used and candidate vaccine adjuvants are particulate in nature, but their mechanism of action is not well understood. Here, we show that particulate adjuvants, including biodegradable poly(lactide- co -glycolide) (PLG) and polystyrene microparticles, dramatically enhance secretion of interleukin-1β (IL-1β) by dendritic cells (DCs). The ability of particulates to promote IL-1β secretion and caspase 1 activation required particle uptake by DCs and NALP3. Uptake of microparticles induced lysosomal damage, whereas particle-mediated enhancement of IL-1β secretion required phagosomal acidification and the lysosomal cysteine protease cathepsin B, suggesting a role for lysosomal damage in inflammasome activation. Although the presence of a Toll-like receptor (TLR) agonist was required to induce IL-1β production in vitro, injection of the adjuvants in the absence of TLR agonists induced IL-1β production at the injection site, indicating that endogenous factors can synergize with particulates to promote inflammasome activation. The enhancement of antigen-specific antibody production by PLG microparticles was independent of NALP3. However, the ability of PLG microparticles to promote antigen-specific IL-6 production by T cells and the recruitment and activation of a population of CD11b + Gr1 − cells required NALP3. Our data demonstrate that uptake of microparticulate adjuvants by DCs activates the NALP3 inflammasome, and this contributes to their enhancing effects on innate and antigen-specific cellular immunity.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Gout-associated uric acid crystals activate the NALP3 inflammasome
Martinon, F., Pétrilli, V., Mayor, A., Tardivel, A., & Tschopp, J. (2006) · Nature · doi:10.1038/nature04516 · Cited by 5,326
Self-citationCryopyrin activates the inflammasome in response to toxins and ATP
Mariathasan, S., Weiss, D. S., Newton, K., McBride, J., O'Rourke, K., Roose-Girma, M., Lee, W. P., Weinrauch, Y., Monack, D. M., & Dixit, V. M. (2006) · Nature · doi:10.1038/nature04515 · Cited by 3,080 · cited 1×
“A number of factors can activate the NALP3 inflammasome, including microbial nucleic acids (22), muramyl dipeptide, toxins (23, 24), asbestos, silica (25), alum (11), and the endogenous stimuli, ATP, (24) monosodium urate, and calcium pyrophosphate dihydrate crystals (26).”
BackgroundHornung, V., Bauernfeind, F., Halle, A., Samstad, E. O., Kono, H., Rock, K. L., Fitzgerald, K. A., & Latz, E. (2008) · Nature Immunology · doi:10.1038/ni.1631 · Cited by 3,065
Lutz, M. B., Kukutsch, N., Ogilvie, A. L. J., Rößner, S., Koch, F., Romani, N., & Schuler, G. (1999) · Journal of Immunological Methods · doi:10.1016/s0022-1759(98)00204-x · Cited by 2,966
Innate Immune Activation Through Nalp3 Inflammasome Sensing of Asbestos and Silica
Dostert, C., Pétrilli, V., Van Bruggen, R., Steele, C., Mossman, B. T., & Tschopp, J. (2008) · Science · doi:10.1126/science.1156995 · Cited by 2,658
Self-citationHigh-mobility group box 1 protein (HMGB1): nuclear weapon in the immune arsenal
Lotze, M. T., & Tracey, K. J. (2005) · Nature Reviews Immunology · doi:10.1038/nri1594 · Cited by 2,487
The NALP3 inflammasome is involved in the innate immune response to amyloid-β
Halle, A., Hornung, V., Petzold, G. C., Stewart, C. R., Monks, B. G., Reinheckel, T., Fitzgerald, K. A., Latz, E., Moore, K. J., & Golenbock, D. T. (2008) · Nature Immunology · doi:10.1038/ni.1636 · Cited by 2,441
Agostini, L., Martinon, F., Burns, K., McDermott, M. F., Hawkins, P. N., & Tschopp, J. (2004) · Immunity · doi:10.1016/s1074-7613(04)00046-9 · Cited by 1,768 · cited 1×
“The NALP2/ NALP3 inflammasome contains NALP2 or NALP3, the adaptor proteins CARDINAL and ASC, and caspase 1 (19).”
BackgroundSelf-citationNatural adjuvants: Endogenous activators of dendritic cells
Gallucci, S., Lolkema, M., & Matzinger, P. (1999) · Nature Medicine · doi:10.1038/15200 · Cited by 1,602
Crucial role for the Nalp3 inflammasome in the immunostimulatory properties of aluminium adjuvants
Eisenbarth, S. C., Colegio, O. R., O’Connor, W., Sutterwala, F. S., & Flavell, R. A. (2008) · Nature · doi:10.1038/nature06939 · Cited by 1,542
Cited by
Targeting the NLRP3 inflammasome in inflammatory diseases
Mangan, M. S. J., Olhava, E. J., Roush, W. R., Seidel, H. M., Glick, G. D., & Latz, E. (2018) · Nature Reviews Drug Discovery · doi:10.1038/nrd.2018.97 · Cited by 1,885
Molecular mechanisms regulating NLRP3 inflammasome activation
Jo, E.-K., Kim, J. K., Shin, D.-M., & Sasakawa, C. (2016) · Cellular & Molecular Immunology · doi:10.1038/cmi.2015.95 · Cited by 1,378
Masters, S. L., Dunne, A., Subramanian, S. L., Hull, R. L., Tannahill, G. M., Sharp, F. A., Becker, C., Franchi, L., Yoshihara, E., Chen, Z., et al. (2010) · Nature Immunology · doi:10.1038/ni.1935 · Cited by 1,330
Self-citationBio-inspired, bioengineered and biomimetic drug delivery carriers
Yoo, J.-W., Irvine, D. J., Discher, D. E., & Mitragotri, S. (2011) · Nature Reviews Drug Discovery · doi:10.1038/nrd3499 · Cited by 1,236
Towards an understanding of the adjuvant action of aluminium
Marrack, P., McKee, A. S., & Munks, M. W. (2009) · Nature Reviews Immunology · doi:10.1038/nri2510 · Cited by 887
The Sterile Inflammatory Response
Rock, K. L., Latz, E., Ontiveros, F., & Kono, H. (2010) · Annual Review of Immunology · doi:10.1146/annurev-immunol-030409-101311 · Cited by 865
Advances in Biomaterials for Drug Delivery
Fenton, O. S., Olafson, K. N., Pillai, P. S., Mitchell, M. J., & Langer, R. (2018) · Advanced Materials · doi:10.1002/adma.201705328 · Cited by 855
Autophagy Controls IL-1β Secretion by Targeting Pro-IL-1β for Degradation
Harris, J., Hartman, M., Roche, C., Zeng, S. G., O'Shea, A., Sharp, F. A., Lambe, E. M., Creagh, E. M., Golenbock, D. T., Tschopp, J., et al. (2011) · Journal of Biological Chemistry · doi:10.1074/jbc.m110.202911 · Cited by 794
Self-citationSynthetic Nanoparticles for Vaccines and Immunotherapy
Irvine, D. J., Hanson, M. C., Rakhra, K., & Tokatlian, T. (2015) · Chemical Reviews · doi:10.1021/acs.chemrev.5b00109 · Cited by 763
Niikura, K., Matsunaga, T., Suzuki, T., Kobayashi, S., Yamaguchi, H., Orba, Y., Kawaguchi, A., Hasegawa, H., Kajino, K., Ninomiya, T., et al. (2013) · ACS Nano · doi:10.1021/nn3057005 · Cited by 638
Engineering synthetic vaccines using cues from natural immunity
Irvine, D. J., Swartz, M. A., & Szeto, G. L. (2013) · Nature Materials · doi:10.1038/nmat3775 · Cited by 594
Materials engineering for immunomodulation
Hubbell, J. A., Thomas, S. N., & Swartz, M. A. (2009) · Nature · doi:10.1038/nature08604 · Cited by 561
Oyewumi, M. O., Kumar, A., & Cui, Z. (2010) · Expert Review of Vaccines · doi:10.1586/erv.10.89 · Cited by 547
Kim, J., Li, W. A., Choi, Y., Lewin, S. A., Verbeke, C. S., Dranoff, G., & Mooney, D. J. (2015) · Nature Biotechnology · doi:10.1038/nbt.3071 · Cited by 541
Inflammasomes in liver diseases
Szabo, G., & Csak, T. (2012) · Journal of Hepatology · doi:10.1016/j.jhep.2012.03.035 · Cited by 495
NLRP3 inflammasome in neurological diseases, from functions to therapies
Song, L., Pei, L., Yao, S., Wu, Y., & Shang, Y. (2017) · Frontiers in Cellular Neuroscience · doi:10.3389/fncel.2017.00063 · Cited by 467
Uric acid as a danger signal in gout and its comorbidities
Rock, K. L., Kataoka, H., & Lai, J.-J. (2013) · Nature Reviews Rheumatology · doi:10.1038/nrrheum.2012.143 · Cited by 444
Lynn, G. M., Laga, R., Darrah, P. A., Ishizuka, A. S., Balaci, A. J., Dulcey, A. E., Pechar, M., Pola, R., Gerner, M. Y., Yamamoto, A., et al. (2015) · Nature Biotechnology · doi:10.1038/nbt.3371 · Cited by 440
Mechanism of Immunopotentiation and Safety of Aluminum Adjuvants
HogenEsch, H. (2013) · Frontiers in Immunology · doi:10.3389/fimmu.2012.00406 · Cited by 430
Alum interaction with dendritic cell membrane lipids is essential for its adjuvanticity
Flach, T. L., Ng, G., Hari, A., Desrosiers, M. D., Zhang, P., Ward, S. M., Seamone, M. E., Vilaysane, A., Mucsi, A. D., Fong, Y., et al. (2011) · Nature Medicine · doi:10.1038/nm.2306 · Cited by 405
Self-citationEngineering Nano‐ and Microparticles to Tune Immunity
Moon, J. J., Huang, B., & Irvine, D. J. (2012) · Advanced Materials · doi:10.1002/adma.201200446 · Cited by 404
Optimizing the utilization of aluminum adjuvants in vaccines: you might just get what you want
HogenEsch, H., O’Hagan, D. T., & Fox, C. B. (2018) · npj Vaccines · doi:10.1038/s41541-018-0089-x · Cited by 391
Self-citationNanotechnology for COVID-19: Therapeutics and Vaccine Research
Chauhan, G., Madou, M. J., Kalra, S., Chopra, V., Ghosh, D., & Martinez-Chapa, S. O. (2020) · ACS Nano · doi:10.1021/acsnano.0c04006 · Cited by 385
Inflammasomes: current understanding and open questions
Bauernfeind, F., Ablasser, A., Bartok, E., Kim, S., Schmid-Burgk, J., Cavlar, T., & Hornung, V. (2011) · Cellular and Molecular Life Sciences · doi:10.1007/s00018-010-0567-4 · Cited by 359
McNeela, E. A., Burke, Á., Neill, D. R., Baxter, C., Fernandes, V. E., Ferreira, D., Smeaton, S., El-Rachkidy, R., McLoughlin, R. M., Mori, A., et al. (2010) · PLoS Pathogens · doi:10.1371/journal.ppat.1001191 · Cited by 355
Self-citationThe Inflammasomes in Kidney Disease
Anders, H.-J., & Muruve, D. A. (2011) · Journal of the American Society of Nephrology · doi:10.1681/asn.2010080798 · Cited by 351
Novel approaches for vaccine development
Gebre, M. S., Brito, L. A., Tostanoski, L. H., Edwards, D. K., Carfi, A., & Barouch, D. H. (2021) · Cell · doi:10.1016/j.cell.2021.02.030 · Cited by 347
Molecular mechanisms involved in inflammasome activation
Bryant, C., & Fitzgerald, K. A. (2009) · Trends in Cell Biology · doi:10.1016/j.tcb.2009.06.002 · Cited by 347
Inflammasomes: too big to miss
Stutz, A., Golenbock, D. T., & Latz, E. (2009) · Journal of Clinical Investigation · doi:10.1172/jci40599 · Cited by 346
Watson, D. S., Endsley, A. N., & Huang, L. (2012) · Vaccine · doi:10.1016/j.vaccine.2012.01.070 · Cited by 322
Alum adjuvant: some of the tricks of the oldest adjuvant
Kool, M., Fierens, K., & Lambrecht, B. N. (2012) · Journal of Medical Microbiology · doi:10.1099/jmm.0.038943-0 · Cited by 318
Nanoparticle-Based Vaccines Against Respiratory Viruses
Al-Halifa, S., Gauthier, L., Arpin, D., Bourgault, S., & Archambault, D. (2019) · Frontiers in Immunology · doi:10.3389/fimmu.2019.00022 · Cited by 299
Critical functions of priming and lysosomal damage for NLRP3 activation
Hornung, V., & Latz, E. (2010) · European Journal of Immunology · doi:10.1002/eji.200940185 · Cited by 297
The role of TLRs, NLRs, and RLRs in mucosal innate immunity and homeostasis
Lavelle, E. C., Murphy, C., O'Neill, L. A. J., & Creagh, E. M. (2010) · Mucosal Immunology · doi:10.1038/mi.2009.124 · Cited by 293
Self-citationDAMPs as mediators of sterile inflammation in aging-related pathologies
Feldman, N., Rotter-Maskowitz, A., & Okun, E. (2015) · Ageing Research Reviews · doi:10.1016/j.arr.2015.01.003 · Cited by 283
“This process requires acidification of the phagosome nd depends in part on the lysosomal protease cathepsin-B (Halle t al., 2008; Hornung et al., 2008; Sharp et al., 2009).”
BackgroundThe Control of Adaptive Immune Responses by the Innate Immune System
Schenten, D., & Medzhitov, R. (2011) · Advances in Immunology · doi:10.1016/b978-0-12-387664-5.00003-0 · Cited by 279
Shimada, T., Park, B. G., Wolf, A. J., Brikos, C., Goodridge, H. S., Becker, C. A., Reyes, C. N., Miao, E. A., Aderem, A., Götz, F., et al. (2010) · Cell Host & Microbe · doi:10.1016/j.chom.2009.12.008 · Cited by 274
The path to a successful vaccine adjuvant – ‘The long and winding road’
O’Hagan, D. T., & De Gregorio, E. (2009) · Drug Discovery Today · doi:10.1016/j.drudis.2009.02.009 · Cited by 274
Self-citationSun, B., Ji, Z., Liao, Y.-P., Wang, M., Wang, X., Dong, J., Chang, C. H., Li, R., Zhang, H., Nel, A. E., et al. (2013) · ACS Nano · doi:10.1021/nn404211j · Cited by 262
Nicolete, R., Santos, D. F. D., & Faccioli, L. H. (2011) · International Immunopharmacology · doi:10.1016/j.intimp.2011.05.014 · Cited by 261
Controlling timing and location in vaccines
Irvine, D. J., Aung, A., & Silva, M. (2020) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2020.06.019 · Cited by 254
Luo, Y.-H., Chang, L. W., & Lin, P. (2015) · BioMed Research International · doi:10.1155/2015/143720 · Cited by 254
Nanoparticle-Based Delivery Systems for Vaccines
Bezbaruah, R., Chavda, V. P., Nongrang, L., Alom, S., Deka, K., Kalita, T., Ali, F., Bhattacharjee, B., & Vora, L. (2022) · Vaccines · doi:10.3390/vaccines10111946 · Cited by 253
Recent progress in adjuvant discovery for peptide-based subunit vaccines
Azmi, F., Ahmad Fuaad, A. A. H., Skwarczynski, M., & Toth, I. (2014) · Human Vaccines & Immunotherapeutics · doi:10.4161/hv.27332 · Cited by 239
“The aggregation complex usually exhibits similar dimensions to pathogens, which encourages their uptake into APC via phagocytosis.(14) Hence these adjuvants may contribute to the maturation of APC.”
BackgroundMacrophage and dendritic cell phenotypic diversity in the context of biomaterials
Kou, P. M., & Babensee, J. E. (2011) · Journal of Biomedical Materials Research Part A · doi:10.1002/jbm.a.32971 · Cited by 190
The impact of nanoparticle ligand density on dendritic-cell targeted vaccines
Bandyopadhyay, A., Fine, R. L., Demento, S., Bockenstedt, L. K., & Fahmy, T. M. (2011) · Biomaterials · doi:10.1016/j.biomaterials.2010.12.054 · Cited by 141
Ballester, M., Nembrini, C., Dhar, N., de Titta, A., de Piano, C., Pasquier, M., Simeoni, E., van der Vlies, A. J., McKinney, J. D., Hubbell, J. A., et al. (2011) · Vaccine · doi:10.1016/j.vaccine.2011.07.039 · Cited by 130
Nanoparticle impact on innate immune cell pattern-recognition receptors and inflammasomes activation
Silva, A. L., Peres, C., Conniot, J., Matos, A. I., Moura, L., Carreira, B., Sainz, V., Scomparin, A., Satchi-Fainaro, R., Préat, V., et al. (2017) · Seminars in Immunology · doi:10.1016/j.smim.2017.09.003 · Cited by 95
Metadata
- Authors
- Sharp, F. A., Ruane, D., Claass, B., Creagh, E., Harris, J., Malyala, P., Singh, M., O'Hagan, D. T., Pétrilli, V., Tschopp, J., O'Neill, L. A. J., & Lavelle, E. C.
- Venue
- Proceedings of the National Academy of Sciences
- Published
- 2009-01-20
- Volume
- 106
- Issue
- 3
- Pages
- 870-875
- ISSN
- 0027-8424 (ISSN-L)
- 1091-6490
- OpenAlex
- W2122708413
- Cited by
- 540
- References
- 43
- FWCI
- 17.76
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.